pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rare Disease
drug
save

Rare Disease

Preclinicalupdated 6mo ago
by Dawn Sea Therapeutics
Preclinical
community read0 votes

🐶 often sniffed alongside

top 8
  • tagOncology6 co-mentions · 2 sources
  • tagRare Disease5 co-mentions · 5 sources
  • tagPulmonology2 co-mentions · 2 sources
  • tagNSCLC2 co-mentions · 2 sources
  • drugSL-9012 co-mentions · 2 sources
  • drugUndisclosed2 co-mentions · 2 sources
  • companyStemline Therapeutics Inc2 co-mentions · 2 sources
  • companyJohns Hopkins University1 co-mentions · 1 sources

all catalysts(2)

pdufa · 2
Jan 15, 2027
pdufa
$RARE17.73+6.17%
in 2mo
Rare Disease PDUFA 2027-01-15
Rare Disease
→
Mar 29, 2027
pdufa
in 4mo
Rare Disease PDUFA 2027-03-29
Rare Disease
→

News(10)

  • Sanofi gains FDA clearance for Gaucher disease pill
    The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
    biopharma_dive · 5h ago
  • nChroma halves workforce, BioXcel lets execs go
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 7h ago
  • Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
    The go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
    biospace · 7h ago
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    biospace · 8h ago
  • Ramping up: 3 biotechs growing their workforce after series C raises
    Biotechs that announced series C financing this year and are hiring include one that secured $140 million and has locations in London and Massachusetts.
    biospace · 18h ago
  • White House pulls nomination for FDA nominee Overton
    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
    biopharma_dive · 1d ago
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    biospace · 1d ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 1d ago
  • 5 acquisitions that forced Big Pharmas to co-parent
    Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…
    biospace · 1d ago
  • White House yanks Overton nomination hours before committee vote
    The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.
    biospace · 1d ago
view all news mentions →
indication
Unspecified Rare Disease
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?